Abstract In the management of COPD with respiratory failure two types of non invasive ventilation, continuous positive airway pressure and bilevel positive airway pressure (CPAP and BIPAP) were emerged with the aim of correcting gas exchange abnormalities and avoiding endotracheal intubation.
Introduction
Noninvasive positive-pressure ventilation (NPPV) has been used increasingly to treat acute respiratory failure (ARF). The best indications for its use are ARF in patients with COPD exacerbations, acute pulmonary edema, and immunocompromised states [1] .
Two noninvasive methods for applying positive respiratory pressure exist as follows: by mask with continuous positive pressure in the airways (continuous positive airway pressure) or by ventilation with 2 levels of pressure (bilevel positive pressure ventilation) [2] . In the case of continuous positive airway pressure, the predetermined value of pressure remains constant during the entire respiratory cycle, and the respiratory work is completely performed by the patient. During bilevel pressure ventilation, the pressure is higher during inspiration and decreases during expiration. It is a modality that supports inspiration and, therefore, directly reduces the patient's respiratory work. Even though evidence exists in the literature about the advantages of the use of the face mask with positive pressure in the airways for treating patients with acute cardiogenic pulmonary edema, doubts about the best ventilatory modality persist, because most studies have been limited to analyzing the effects of using this method [3] .
CPAP, BIPAP and other non-invasive ventilation modes have been shown to be effective management tools for chronic obstructive pulmonary disease and acute respiratory failure [4] .
Bilevel positive airway pressure is used when positive airway pressure is needed with the addition of pressure support. Common situations where positive airway pressure is indicated is any disease where taking a breath is difficult. This includes pneumonia, chronic obstructive pulmonary disease, asthma and status asthmaticus in children [5, 6] .
Biphasic/bilevel as a mode of ventilation was first presented in 1988 by Professor Benzer of Innsbruck and his group. His theory consisted of alternating PEEP levels [7] . This was the first time the acronym BIPAP was used and was followed in 1989 with the publication of a new approach to ventilatory technique [8] by Baum & Benzer which was also the first full year of commercial introduction of ''Biphasic Positive Airway Pressure'' as an integrated mode of ventilation on the Evita ventilator. This concept was introduced as a positive adjunct to weaning from ventilator support.
Aim of the work
To evaluate and compare the effectiveness of 2 types of noninvasive respiratory support systems, continuous positive airway pressure, and bilevel positive pressure ventilation in treatment of acute exacerbation of chronic obstructive pulmonary disease:
Patients and methods 
1-Patients
, major confusion with day time sleepiness or agitation, 0 (4), major agitation.
Exclusion criteria
Patients were excluded from this study if they had any of the following:
-Indication for endotracheal intubation.
-Hypotension defined as systolic blood pressure <90 mmHg and diastolic blood pressure <60 mmHg. -Presence of ventricular or atrial arrhythmia. -Inability to cooperate with the fitting and wearing of the face mask. -Presence of upper airway obstruction or facial trauma or presence of tracheostomy.
II-Methods
All the patients were subjected to the following: History taking, clinical examination, plain X-ray chest, ECG, and arterial blood gasses analysis on admission and after 1, 6, 12 h and on second day. Patients were classified into 3 groups: Monitoring of the patients during study -Clinical observation for consciousness level,arterial blood pressure, arterial blood gasses presetting, and after 1, 6, and 12 h, and on second day.
Invasive mechanical ventilation was initiated for any patient who developed criteria necessitating invasive mechanical ventilation.
Weaning from CPAP or BI PAP
The patient was weaned from non invasive ventilatoy support when the patient fulfilled the criteria for separation which were (RR < 30/min, PaO 2 > 60 mmHg, PaCO 2 < 50 mmHg, pH > 7.35).
Results

Tables 1-11.
Discussion
This study included 60 patients with acute exacerbation of chronic obstructive pulmonary disease (COPD) (48 males and 12 females)with age ranging from (51-69 years) admitted to Chest Department and Respiratory Care Unit in Chest Department, Sayed Galal University Hospital, Al Azhar University during the period between May 2011 and February 2012.
These patients were randomly classified into 3 groups.
-Group (1) CPAP group; -Group (2) BIPAP group; -Group (3) standard group.
There was no statistically significant difference between patients of the three groups as regard sex (p value 0.732) and age (p value 0.621) Tables 1 and 2. Clinical assessment for the patients of all groups at time of admission, Table 3 , revealed no statistically significant difference as regard respiratory rate, pulse, systolic and diastolic blood pressure (SBP and DBP) and conscious level with p value (0.767, 0.252, 0.350, 0.441 and 0.317) respectively.
Assessment of arterial blood gasses at time of admission Table 4 revealed that there was no statistically significant difference between patients of the three groups as regard PaO 2 , PaCO 2 , O 2 saturation and pH with p value (0.127, 0.077. 0.098 and 0.998) respectively.
In this study there was improvement in PaO 2 in patients of group 2 (BIPAP group) during the follow up period after 1, 6, 12 h and on second day, Table 5 with statistically significant improvement after 6 and 12 h and on second day with p value (0.013, 0.001 and 0.012) respectively. These results are in agreement with Strumpf et al. [9] who studied the effect of nocturnal positive pressure ventilation BIPAP via nasal mask in patients with severe chronic obstructive pulmonary disease.
In this study there was significant improvement in PaCO 2 in patients of group 2 (Bipap group) after 1, 6, 12 h and on second day in comparison to group [1] (CPAP group) and group [3] (standard group), Table 6 . These results are in accordance with those reported by Casanova et al. [10] , who studied the effect of nocturnal nasal positive pressure ventilation in patients with severe COPD, and Krachman et al. [11] , who evaluated the effect of non invasive BIPAP ventilation on gas exchange and sleep in COPD patients.
Clini et al. [12] evaluated the effect of early use of noninvasive ventilation on gas exchange in patients with acute exacerbation of COPD and concluded that reduction of hypercapnia was greater in patients who received BIPAP ventilation. Also Strumpf et al. [9] found that the reduction of hypercapnia noted on continuous nocturnal monitoring of end-tidal carbon dioxide tension and PaCO 2 is greater than that observed by Meecham Jones et al. [13] who studied the effect of nasal pressure support ventilation plus oxygen compared with oxygen therapy alone in hypercapnic COPD. The extent of reduced hypercapnia which was greater in comparison with the study done by Meecham Jones et al. [13] suggesting that the effectiveness of bilevel NIPPV is greater in COPD patients with a higher baseline PaCO 2 . Nocturnal PaCO 2 monitoring may be a more dynamic measure of effectiveness of bilevel NIPPV in reduction of hypercapnia in patients with severe stable COPD than arterial blood gasses alone. In this study there was improvement in O2 saturation in patients of group 2 (BIPAP group), Table 7 , during the follow up period after 1, 6, 12 h and on second day with statistically significant improvement after 12 h and in second day (p value 0.0492 and 0.041).
Comparing group 1 (CPAP group) to group 2 (BIPAP group) using Tukey's test, revealed that group 1 showed improved O 2 saturation in first hour and after 6 h, this may be explained by intolerance to the use of BIPAP. by the time, O 2 saturation have been significantly improved after 12 h and on second day.
In this study there was mild improvement in arterial pH in patients of group 2 (BIPAP group), Table 8 , in comparison to group 1 after 1, 6 h and on second day with significant improvement after 12 h (p value 0.001). These results are in agree with Plant et al. [14] who found more rapid improvement in arterial PH, respiratory rate and breathlessness in the NIP-PV group compared to the control group however, the mortality benefit was not apparent in patients with a pH < 7.3.
In this study it was found that the duration of ICU stay, Table 9 , was significantly shorter in patients of group 1 and 2 in comparison to group 3 with less, but non significant, decrease in duration of ICU stay in group 2 in comparison to group 1. These results are in accordance with those reported by Brochard et al. [15] who showed that pressure support ventilation administered via a face mask significantly reduced the need for intubation, the duration of mechanical ventilation and ICU length of stay. A more recent study by Kolodzie et al. [16] reported that the use of bilevel noninvasive positive pressure ventilation (NIPPV) in acute respiratory failure due to COPD exacerbation has been shown to reduce the need for intubation and mechanical ventilation, the length of hospital stay, and mortality.
In this study comparison between complications in group 1 (CPAP group) and group 2 (BIPAP group), Table 10 , showed no significant difference between the two groups (p value 0.765). These results are in accordance with Lin [17] who reported that the most prevalent complaints were related to asynchrony and sleep.
Also kolodzie et al. [16] reported that the most prevalent complaints were related to asynchrony and sleep, inability to tolerate pressure-level settings, dry nose and/or mouth or mask/interface intolerance due to problems such as leak or nasal skin lesions. Two studies reported bilevel NIPPV intolerance with no reasons cited [18] .
In this study it was found that there was a significant decrease in the rate of ETI among patients of group 2 (BIPAP group) (20%) compared to group 1 (45%) and group 3 (60%) as shown in Table 11 with p value (0.033). These results are in agreement with the large multi center Europian trial conducted by Lightowler et al. [19] which showed that COPD patients with acute exacerbation who randomized to NIPPV had significantly lower ETI rate than conventionally treated patients (26% versus 74%) respectively. 
